CRIS Current Research Information System
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishEpidemiological studies have suggested that aspirin may have a protective effect against prostate cancer, but the evidence is still limited and inconsistent The role of aspirin in prostate cancer risk was analysed in a multicentric case-control study conducted in Italy between 1991 and 2002, including 1261 incident cases of carcinoma of the prostate and 1131 hospital controls. A total of 115 (9.1%) cases versus 90 (8.0%) controls reported regular aspirin use. The multivariate odds ratio (OR) for regular aspirin users was 1.10 (95% confidence interval (95% CI) 0.81-1.50). No relation was found with duration of use (OR = 1.03 for < 5 years, and 1.17 for >= 5 years) and time since first use (OR = 1.03 for < 10 years, and 1.35 for >= 10 years). These findings do not support a protective role of regular aspirin use on prostate cancer risk.
| Titolo: | Aspirin and the risk of prostate cancer | |
| Autore/i: | Bosetti C; Talamini R; Negri E; Franceschi S; Montella M; La Vecchia C | |
| Autore/i Unibo: | ||
| Anno: | 2006 | |
| Rivista: | ||
| Digital Object Identifier (DOI): | http://dx.doi.org/10.1097/01.cej.0000180665.04335.de | |
| Abstract: | Epidemiological studies have suggested that aspirin may have a protective effect against prostate cancer, but the evidence is still limited and inconsistent The role of aspirin in prostate cancer risk was analysed in a multicentric case-control study conducted in Italy between 1991 and 2002, including 1261 incident cases of carcinoma of the prostate and 1131 hospital controls. A total of 115 (9.1%) cases versus 90 (8.0%) controls reported regular aspirin use. The multivariate odds ratio (OR) for regular aspirin users was 1.10 (95% confidence interval (95% CI) 0.81-1.50). No relation was found with duration of use (OR = 1.03 for < 5 years, and 1.17 for >= 5 years) and time since first use (OR = 1.03 for < 10 years, and 1.35 for >= 10 years). These findings do not support a protective role of regular aspirin use on prostate cancer risk. | |
| Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
Copyright © 2022